{"analyses":[{"ciLowerLimit":"7.8","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"12","estimateComment":"KM estimates for median TTP with associated 95% CI","groupIds":["OG000"],"nonInferiorityType":"OTHER","paramType":"median TTP","paramValue":"10.6"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.8","upperLimit":"12","value":"10.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Time from date of first dose of study treatment to the date of first documented evidence of PD or date of censoring for the participants not progressed. The censoring date is the last adequate tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ibrutinib (I): I 840 mg orally, once daily continuously starting day 1 of Cycle (C) 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation Bortezomib (B): C 1-8: (21-day C): B 1.3 mg/m\\^2 sub-cutaneously on days 1, 4, 8, and 11 of each C C 9-12: (42-day C): B 1.3 mg/m\\^2 sub-cutaneously on days 1, 8, 22 and 29 of each C Dexamethasone (D): C 1-8: (21-day C): D 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each C C 9-12: (42-day C): D 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each C C 13+ (28-day C): D 40 mg orally once weekly Dose adjustment of D to 10 mg on days specified during C 1-12 and 20 mg weekly during C 13+ is recommended for subjects \\>75 years of age.\n\nFollowing implementation of Protocol Amendment 4, D administration was reduced to Days 1, 4, 8, and 11 during each 21-day C (C 1-8) and on Days 1, 8, 22 and 29 on each 42-day C (C 9-12) and unchanged thereafter","id":"OG000","title":"Ibrutinib+ Bortezomib+ Dexamethasone"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"The median time on study was 19.6 months (range: 0.16+, 24.64).","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Months"}